Polonia - poloneză - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

apc instytut sp. z o.o. - sitagliptin hydrochloride monohydrate + metformini hydrochloridum - tabletki o zmodyfikowanym uwalnianiu - 50 mg + 1000 mg

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

fgk representative service gmbh - sufentanyl - ból, pooperacyjny - Środki znieczulające - zalviso jest wskazany w leczeniu ostrego umiarkowanego i ciężkiego bólu pooperacyjnego u dorosłych pacjentów.

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

tetris pharma b.v - glukagon - cukrzyca - hormony trzustki, hormony glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - okulistyka - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - Środki przeciwnowotworowe - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

biogen netherlands b.v. - sól sodowa nusinersen - zanik mięśni, kręgosłup - inne leki na układ nerwowy - spinraza jest wskazany w leczeniu 5-rdzeniowego zaniku mięśni.

Polonia - poloneză - URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych)

aflofarm farmacja polska sp. z o.o. - cytisinum - tabletki - 1,5 mg

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - brexpiprazole - schizofrenia - psycholeptyki - leczenie schizofrenii.

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

albireo - odevixibat - cholestasis, intrahepatic - terapia żółci i wątroby - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 i 5.

Uniunea Europeană - poloneză - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - szpiczak mnogi - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.